The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma

Journal of the Neurological Sciences

Volumn 294, Issue 1-2, 2010, Pages 112-118

  Kim, Bomi ^a,b,c   Myung, Jae Kyung ^b   Seo, Ja Hee ^b   Park, Chul Kee ^b,c   Paek, Sun Ha ^b,c   Kim, Dong Gyu ^b,c   Jung, Hee Won ^b,c   Park, Sung Hye ^b,c  

^a Inje University   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Brain neoplasm; Epidermal growth factor; Glioblastoma; Prognosis; Tumor suppressor protein p53

Indexed keywords

ANTIBODY; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MOLECULAR MARKER; NIMUSTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; EGFR PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GAMMA KNIFE RADIOSURGERY; GENE AMPLIFICATION; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR VOLUME; AGE; BRAIN; BRAIN NEOPLASMS; INFRATENTORIAL NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; SUPRATENTORIAL NEOPLASMS; SURGERY; SURVIVAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGE FACTORS; BRAIN; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFRATENTORIAL NEOPLASMS; MALE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77953287969     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.03.019     Document Type: Article

References (25)

1. Louis DN O.H., and Wiestler OD C.W.K. WHO Classification of Tumours of the Central Nervous System. 4th ed (2007), IARC press
2. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine 352 10 (Mar. 2005) 997-1003
3. Ohgaki H., and Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170 5 (May 2007) 1445-1453
4. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 19 (Nov. 2005) 2012-2024
5. Kumar V., Fausto N., and Abbas A. Robbins & Cotran Pathologic Basis of Disease. 7th ed (2004), Saunders
6. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 9 (May 2005) 643-655
7. Smith J.S., Tachibana I., Passe S.M., Huntley B.K., Borell T.J., Iturria N., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93 16 (Aug. 2001) 1246-1256
8. Joensuu H., Puputti M., Sihto H., Tynninen O., and Nupponen N.N. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 207 2 (Oct. 2005) 224-231
9. Puputti M., Tynninen O., Sihto H., Blom T., Maenpaa H., Isola J., et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 4 12 (Dec. 2006) 927-934
10. Xie D., Zeng Y.X., Wang H.J., Tai L.S., Wen J.M., Tao Y., et al. Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway. Acta Neuropathol (Berl) 110 5 (Nov. 2005) 481-489
11. Steidl C., Simon R., Burger H., Brinkschmidt C., Hertle L., Bocker W., et al. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol 198 1 (Sep. 2002) 115-120
12. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 20 (Oct. 2003) 3798-3807
13. Jeon Y.K., Sung S.-W., Chung J.-H., Park W.-S., Seo J.-W., Kim C.W., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54 3 (2006) 387-398
14. Buckley A.F., Burgart L.J., Sahai V., and Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129 2 (Feb. 2008) 245-251
15. Ellis I., and Dei Tos A.P. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. Eur J Cancer 41 10 (Jul. 2005) 1383-1392
16. Marquez A., Wu R., Zhao J., Tao J., and Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 13 1 (2004) 1-8
17. Buckley A.F., and Kakar S. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 15 3 (Sep. 2007) 305-309
18. Okada Y., Hurwitz E.E., Esposito J.M., Brower M.A., Nutt C.L., and Louis D.N. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer research 63 2 (Jan. 2003) 413-416
19. Gil-Benso R., Lopez-Gines C., Benito R., Lopez-Guerrero J.A., Callaghan R.C., Pellin A., et al. Concurrent EGFR amplification and TP-53 mutation in glioblastomas. Clin Neuropathol 26 5 (Sep.-Oct. 2007) 224-231
20. Nagpal J., Jamoona A., Gulati N.D., Mohan A., Braun A., Murali R., et al. Revisiting the role of p53 in primary and secondary glioblastomas. Anticancer Res 26 6C (Nov.-Dec. 2006) 4633-4639
21. Ganigi P.M., Santosh V., Anandh B., Chandramouli B.A., and Sastry Kolluri V.R. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg 41 6 (Nov.-Dec. 2005) 292-299
22. Puszynski K., Hat B., and Lipniacki T. Oscillations and bistability in the stochastic model of p53 regulation. J Theor Biol 254 2 (Sep. 2008) 452-465
23. Mayo L.D., and Donner D.B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends in Biochemical Sciences 27 9 (2002) 462-467
24. Kleinschmidt-DeMasters B.K., Meltesen L., McGavran L., and Lillehei K.O. Characterization of glioblastomas in young adults. Brain Pathol 16 4 (Oct. 2006) 273-286
25. Lacroix M., Abi-Said D., Fourney D.R., Gokaslan Z.L., Shi W., DeMonte F., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95 2 (Aug. 2001) 190-198